Hangzhou Weiruibao Biopharm

V-Rebio Biopharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to developing innovative small molecule therapies for metabolic and fibrotic diseases. The company focuses on high-potential targets such as nuclear receptors and G protein-coupled receptors (GPCRs) to address significant unmet medical needs in hepatology. Its lead candidate, VRB-001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently undergoing clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). V-Rebio leverages a proprietary drug discovery platform to optimize the safety and efficacy profiles of its pipeline candidates. The company is backed by top-tier venture capital firms, including Qiming Venture Partners and IDG Capital. Through its research and development efforts, V-Rebio aims to provide transformative treatment options for patients suffering from chronic liver conditions and metabolic disorders globally.